HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

A research group led by Assistant Professor Megumi Aimoto and Professor Akira Takahara at the Faculty of Pharmaceutical Sciences, Toho University, revealed that pyrazole-3 (Pyr3), a selective ...

Share on Pinterest New research suggests that there may be more than 10.5 million people in the United States living with atrial fibrillation, that is, three times more cases than experts had ...

PHILADELPHIA (WPVI) -- Most of us have heard of atrial fibrillation, commonly called AFib. The airwaves are filled with commercials for treatments. A Roxborough woman shared her struggle with it, and ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

EAST LANSING, Mich. (WILX) - Michigan State University researchers have developed miniature hearts from human stem cells that ...

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...